Since the early 1980s, research on the mechanisms of penile erection has done much to
clarify erectile physiology and pathophysiology. More recent studies have identified the …

Purpose: Phosphodiesterase type 5 (PDE5) inhibitors have proved to be efficacious, safe,
and well tolerated, in clinical trials and practice, for men with erectile dysfunction (ED) …

The advent of sildenafil (Viagra) for the treat-ment of erectile dysfunction has attracted
widespread interests in phosphodiesterase type 5 (PDE5), the target of sildenafil, 1 and …

Phosphodiesterase-5 (PDE5) inhibitors have been approved by the US Food and Drug
Administration for the treatment of erectile dysfunction and more recently for pulmonary …

Historically, oral phosphodiesterase type 5 inhibitors (PDE5‐i) have been prescribed with an
'as‐necessary'regimen for treating erectile dysfunction (ED), thus addressing primarily …

Erectile dysfunction (ED) is a common medical condition that affects the sexual life of
millions of men. At present, first-line oral pharmacotherapy for most patients with ED is a …

This paper describes our recent efforts to design and synthesise potent and selective PDE5
inhibitors and the use of in vitro predictors of clearance, absorption and permeability to …

Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the
treatment of erectile dysfunction (ED), being recommended as a first line treatment by both …

Erectile dysfunction (ED) is a common medical condition that has a negative impact on men
and their partners. The field has revolutionised over the last two decades and more …

Abstract Introduction Phosphodiesterase type 5 (PDE-5) hydrolyzes cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP, promoting successful corporeal vascular …